SciELO - Scientific Electronic Library Online

vol.83 issue10Anatomical repercussion on the zonular apparatus after a capsular tension ring insertion in swine eyesComparative study of refractive errors in simple congenital myogenic ptosis and control children author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Archivos de la Sociedad Española de Oftalmología

Print version ISSN 0365-6691


MARTINEZ, A.  and  SLOF, J.. Cost-efficacy analysis of fixed combinations of prostaglandin/prostamide for treating glaucoma. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.10, pp.595-600. ISSN 0365-6691.

Objective: To assess the cost-efficacy of three fixed-combination glaucoma treatments currently available in Spain [bimatoprost with timolol (BT)- Ganfort®, latanoprost with timolol (LT)- Xalacom®, and travoprost with timolol (TT)- DuoTrav®]. Methods: Because no studies are available that give a direct comparison of these drugs, a systematic review was carried out to assess their efficacy. Resource consumption and costs were estimated using a model of usual local practice. For each of the three drugs, average and incremental cost-efficacy ratios were determined in terms of euros per percentage point of reduction of intraocular pressure (IOP) over a three-month period. Results: BT reduced IOP by 35.1%, LT by 35.0% and TT by 34.7%. Average cost-efficacy was estimated to be € 5.34 per percentage point of IOP reduction with BT, € 5.40 with LT, and € 5.45 with TT. Incremental cost-efficacy (incremental cost per incremental percentage point of IOP reduction) was estimated to be € 94.65 for LT vs. TT, and was negative for BT vs. TT and BT vs. LT, since in both cases BT was more efficacious and less expensive. Conclusions: Compared to travoprost/timolol and latanoprost/timolol, bimatoprost/timolol appears to be the most economic alternative, with equal or better efficacy and safety results.

Keywords : Glaucoma; cost analysis; beta-blocker; prostaglandin analogue; fixed combinations.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License